Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Vitexin can cooperate with HBO to sensitize the glioma radiotherapy, and its mechanisms may be correlated to the inhibition of HIF-1α protein expression and subsequent decrements of its downstream protein expressions, which finally cause the reduction of antioxidant capacity.
|
31677055 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, HIF-1α-deficient-Treg mice exhibit significantly enhanced animal survival in a murine model of glioma, due to their stymied migratory capacity, explaining their reduced abundance in tumor-bearing mice.
|
30943404 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, IDH mutations can also induce high levels of hypoxia-inducible factor-1α (HIF-1α) to promote glioma invasion.
|
31263678 |
2019 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analyses of receiver operating characteristic curves were done for HIF-1α to discriminate different grades of glioma.
|
29754996 |
2019 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ouabain suppresses the growth and migration abilities of glioma U‑87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF‑1α.
|
29436645 |
2018 |
Glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
|
29625108 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In Vivo Manipulation of HIF-1α Expression During Glioma Genesis.
|
29330804 |
2018 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While HIF1α has been widely studied in cancer, HIF2α offers a potentially more specific and appealing target in glioblastoma given expression in glioma stem cells and not normal neural progenitors, activation in states of chronic hypoxia and expression that correlates with glioma patient survival.
|
30089425 |
2018 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HIF1α regulates single differentiated glioma cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential under hypoxia.
|
28427209 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible factor-1α (HIF1α) contributes substantially to the stemness maintenance of GSCs and resistance of glioma to chemotherapy; thus, we investigated whether HIF1α regulates the resistance or sensitization of glioma cells to chemotherapy in different oxygen levels.
|
28801626 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, in a U87 xenograft tumor model, F2 significantly reduced intra-tumor vessel density and cell proliferation and finally retarded tumor growth, indicating that F2 may be a potential HIF-1 inhibitor and serve as one of candidates for glioma therapy.
|
29156717 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our results suggest that miR-150 modulates the Warburg effect in glioma via VHL/HIF1α and might provide a novel option for future treatments for glioma.
|
28386333 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that DT at clinically achievable concentrations, suppressed HIF-1α accumulation during hypoxic conditions in human GSC and established glioma cell lines.
|
28410215 |
2017 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High levels of HOTTIP and HIF-1α were correlated with glioma metastasis and poor patient prognosis.
|
28886531 |
2017 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that the intracellular domain of stem cell marker CD44 (CD44ICD) is released at hypoxia, binds HIF-2α (but not HIF-1α), enhances HIF target gene activation, and is required for hypoxia-induced stemness in glioma.
|
28813675 |
2017 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that glioma aggression and patient prognosis correlate with HIF1α levels and the stiffness of a tenascin C (TNC)-enriched ECM.
|
27820599 |
2016 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, HSP47 promoted glioma angiogenesis through HIF1α-VEGFR2 signaling.
|
25758142 |
2016 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment.
|
27090014 |
2016 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of HIF-1α enhances the radiation sensitivity of human glioma growth in vitro and in vivo.
|
24859610 |
2015 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
|
25423275 |
2015 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoxia-inducible factor 1α (HIF-1α) activity is one of the major players in hypoxia-mediated glioma progression and resistance to therapies, and therefore the focus of this study was the evaluation of HIF-1α modulation in relation to tumour response with the purpose of identifying imaging biomarkers able to document tumour response to treatment in a murine glioma model.
|
25813354 |
2015 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that the IDH1R132H‑HIF‑1α‑miR‑128a‑Bmi‑1 pathway is involved in glioma cell proliferation.
|
26324126 |
2015 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HIF-1α-p75NTR-EMT axis may play a central role in glioma tumorigenesis.
|
25527128 |
2015 |
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The downregulation of Nrf2 in glioma cells led to much lower accumulation of HIF-1α protein and limited expression of VEGF and other HIF-1α target genes in mimicking hypoxia.
|
24374745 |
2014 |
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The survival time of HIF-1α in grade III and grade IV glioma patients with low IRSs (0-6) was significantly longer than that in such glioma patients with high IRSs (8-12) (P < 0.05).
|
23358800 |
2014 |